We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Solid Tumor Chemotherapy With Mitomycin C

Alvin L. Watne, MD; Dianna Moore, BS; Bedrettin Gorgun, MD
Arch Surg. 1967;95(2):175-178. doi:10.1001/archsurg.1967.01330140013003.
Text Size: A A A
Published online


MITOMYCIN C is an antibiotic derived from the fermentation filtrate of Streptomyces caespitosus, a species of Streptomyces isolated from a soil sample collected in Tokyo in 1955.1 It has a broad spectrum of activity against gram positive and gram negative bacteria, rickettsiae, and certain viruses as well as a high degree of chemotherapeutic activity against numerous transplantable mouse and rat tumors.2 The initial Japanese reports of human trials of mitomycin C indicated that it had demonstrable chemotherapeutic activity against chronic myelogenous leukemia, chorioepithelioma, reticulum cell sarcoma, seminomas, and some epithelial tumors.3 Subsequent reports by American investigators using dosages similar to the Japanese investigators showed the drug to have limited value in leukemias and various sarcomas, but to have severe hematopoietic toxicity.4,5

Methods  This report presents our results using mitomycin C at a somewhat lower dosage schedule in 24 patients with advanced malignant disease arising from solid


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.